Adjuvant Holdings Co Ltd
TSE:4929
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Adjuvant Holdings Co Ltd
Adjuvant Holdings Co Ltd
Cost of Revenue
Adjuvant Holdings Co Ltd
Cost of Revenue Peer Comparison
4911
4527
4927
4452
4967
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Adjuvant Holdings Co Ltd
TSE:4929
|
Cost of Revenue
-¥1.6B
|
CAGR 3-Years
6%
|
CAGR 5-Years
5%
|
CAGR 10-Years
0%
|
|
|
Shiseido Co Ltd
TSE:4911
|
Cost of Revenue
-¥321.6B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-5%
|
|
|
Rohto Pharmaceutical Co Ltd
TSE:4527
|
Cost of Revenue
-¥113.6B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-7%
|
|
|
Pola Orbis Holdings Inc
TSE:4927
|
Cost of Revenue
-¥30.8B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
3%
|
|
|
Kao Corp
TSE:4452
|
Cost of Revenue
-¥968.1B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-5%
|
|
|
Kobayashi Pharmaceutical Co Ltd
TSE:4967
|
Cost of Revenue
-¥78.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-4%
|
See Also
What is Adjuvant Holdings Co Ltd's Cost of Revenue?
Cost of Revenue
-1.6B
JPY
Based on the financial report for Mar 20, 2024, Adjuvant Holdings Co Ltd's Cost of Revenue amounts to -1.6B JPY.
What is Adjuvant Holdings Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
0%
Over the last year, the Cost of Revenue growth was -8%. The average annual Cost of Revenue growth rates for Adjuvant Holdings Co Ltd have been 6% over the past three years , 5% over the past five years .
You don't have any saved screeners yet
